PCRX logo

Pacira BioSciences (PCRX) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

03 February 2011

Indexes:

Not included

Description:

Pacira BioSciences, Inc. is a holding biopharmaceutical company headquartered in Parsippany-Troy Hills, New Jersey, operating through a number of subsidiaries. It was founded in 2006 as Blue Acquisition Corp. It is a leading provider of non-opioid pain relief medications for patients and physicians, as well as non-opioid solutions for surgeons and anesthesiologists in the field of health regeneration. Pacira BioSciences is the only supplier of long-acting non-opioid analgesics. The company's product portfolio includes the following medications: EXPAREL and the iovera system. In addition, the company has a range of products and solutions at various stages of clinical development, such as DepoDexmedetomidine, DepoFoam-based local anesthetic, Pediatric infiltration, Lower extremity nerve block, and others.

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 06, 2024

Recent annual earnings:

Feb 29, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

04 Dec '24 HC Wainwright & Co.
Buy
12 Nov '24 Barclays
Equal-Weight
08 Nov '24 Needham
Buy
07 Nov '24 RBC Capital
Sector Perform
04 Oct '24 RBC Capital
Sector Perform
24 Sept '24 Jefferies
Buy
13 Aug '24 Truist Securities
Sell
12 Aug '24 RBC Capital
Sector Perform
12 Aug '24 Needham
Buy
12 Aug '24 JP Morgan
Underweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Investors who lost money on Pacira BioSciences, Inc. should contact Levi & Korsinsky about an ongoing investigation - PCRX
Investors who lost money on Pacira BioSciences, Inc. should contact Levi & Korsinsky about an ongoing investigation - PCRX
Investors who lost money on Pacira BioSciences, Inc. should contact Levi & Korsinsky about an ongoing investigation - PCRX
PCRX
accesswire.com03 January 2025

NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.

Did Pacira BioSciences, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - PCRX
Did Pacira BioSciences, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - PCRX
Did Pacira BioSciences, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - PCRX
PCRX
accesswire.com02 January 2025

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.

An Investigation Has Commenced on Behalf of Pacira BioSciences, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your PCRX Losses.
An Investigation Has Commenced on Behalf of Pacira BioSciences, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your PCRX Losses.
An Investigation Has Commenced on Behalf of Pacira BioSciences, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your PCRX Losses.
PCRX
accesswire.com20 December 2024

NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.

Here's Why Pacira (PCRX) is a Strong Momentum Stock
Here's Why Pacira (PCRX) is a Strong Momentum Stock
Here's Why Pacira (PCRX) is a Strong Momentum Stock
PCRX
zacks.com18 December 2024

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Levi & Korsinsky Reminds Shareholders of an Investigation into Pacira BioSciences, Inc. (PCRX) Regarding Potential Securities Fraud Allegations
Levi & Korsinsky Reminds Shareholders of an Investigation into Pacira BioSciences, Inc. (PCRX) Regarding Potential Securities Fraud Allegations
Levi & Korsinsky Reminds Shareholders of an Investigation into Pacira BioSciences, Inc. (PCRX) Regarding Potential Securities Fraud Allegations
PCRX
accesswire.com18 December 2024

NEW YORK, NY / ACCESSWIRE / December 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.

Pacira BioSciences, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Pacira BioSciences, Inc. (PCRX)
Pacira BioSciences, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Pacira BioSciences, Inc. (PCRX)
Pacira BioSciences, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Pacira BioSciences, Inc. (PCRX)
PCRX
accesswire.com13 December 2024

NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.

Pacira BioSciences, Inc. (PCRX) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
Pacira BioSciences, Inc. (PCRX) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
Pacira BioSciences, Inc. (PCRX) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
PCRX
accesswire.com12 December 2024

NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.

Pacira BioSciences, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - PCRX
Pacira BioSciences, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - PCRX
Pacira BioSciences, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - PCRX
PCRX
accesswire.com11 December 2024

NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.

Levi & Korsinsky Reminds Pacira BioSciences, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws – PCRX
Levi & Korsinsky Reminds Pacira BioSciences, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws – PCRX
Levi & Korsinsky Reminds Pacira BioSciences, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws – PCRX
PCRX
accesswire.com06 December 2024

NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.

PCRX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Pacira BioSciences, Inc. Investment
PCRX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Pacira BioSciences, Inc. Investment
PCRX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Pacira BioSciences, Inc. Investment
PCRX
accesswire.com05 December 2024

NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.

FAQ

  • What is the primary business of Pacira BioSciences?
  • What is the ticker symbol for Pacira BioSciences?
  • Does Pacira BioSciences pay dividends?
  • What sector is Pacira BioSciences in?
  • What industry is Pacira BioSciences in?
  • What country is Pacira BioSciences based in?
  • When did Pacira BioSciences go public?
  • Is Pacira BioSciences in the S&P 500?
  • Is Pacira BioSciences in the NASDAQ 100?
  • Is Pacira BioSciences in the Dow Jones?
  • When was Pacira BioSciences's last earnings report?
  • When does Pacira BioSciences report earnings?
  • Should I buy Pacira BioSciences stock now?

What is the primary business of Pacira BioSciences?

Pacira BioSciences, Inc. is a holding biopharmaceutical company headquartered in Parsippany-Troy Hills, New Jersey, operating through a number of subsidiaries. It was founded in 2006 as Blue Acquisition Corp. It is a leading provider of non-opioid pain relief medications for patients and physicians, as well as non-opioid solutions for surgeons and anesthesiologists in the field of health regeneration. Pacira BioSciences is the only supplier of long-acting non-opioid analgesics. The company's product portfolio includes the following medications: EXPAREL and the iovera system. In addition, the company has a range of products and solutions at various stages of clinical development, such as DepoDexmedetomidine, DepoFoam-based local anesthetic, Pediatric infiltration, Lower extremity nerve block, and others.

What is the ticker symbol for Pacira BioSciences?

The ticker symbol for Pacira BioSciences is NASDAQ:PCRX

Does Pacira BioSciences pay dividends?

No, Pacira BioSciences does not pay dividends

What sector is Pacira BioSciences in?

Pacira BioSciences is in the Healthcare sector

What industry is Pacira BioSciences in?

Pacira BioSciences is in the Drug Manufacturers - Specialty & Generic industry

What country is Pacira BioSciences based in?

Pacira BioSciences is headquartered in United States

When did Pacira BioSciences go public?

Pacira BioSciences's initial public offering (IPO) was on 03 February 2011

Is Pacira BioSciences in the S&P 500?

No, Pacira BioSciences is not included in the S&P 500 index

Is Pacira BioSciences in the NASDAQ 100?

No, Pacira BioSciences is not included in the NASDAQ 100 index

Is Pacira BioSciences in the Dow Jones?

No, Pacira BioSciences is not included in the Dow Jones index

When was Pacira BioSciences's last earnings report?

Pacira BioSciences's most recent earnings report was on 6 November 2024

When does Pacira BioSciences report earnings?

The next expected earnings date for Pacira BioSciences is 28 February 2025

Should I buy Pacira BioSciences stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions